GLP-1 Market
LLY $1157.08 ▼ -2.3% NVO $37.91 ▼ -1.0% PFE $28.52 ▼ -0.7% VKTX $32.60 ▲ +2.5% KLRA $11.42 ▲ +3.9% GPCR $31.27 ▼ -4.3% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Zodasiran

Company
Arrowhead Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Trial details
  • Completed NCT NCT03747224

    Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

    Not yet reported Arrowhead Pharmaceuticals 93 participants Est. completion 2021-05-17 6 sites Stand-alone
    Other conditions: Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT04832971

    Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

    Not yet reported Arrowhead Pharmaceuticals 204 participants Est. completion 2024-09-25 24 sites Stand-alone
    Other conditions: Mixed Dyslipidemia
    View official trial listing →
  • Terminated NCT NCT05217667

    Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

    Not yet reported Arrowhead Pharmaceuticals 18 participants Est. completion 2025-11-13 7 sites Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Active, not recruiting NCT NCT06712771

    A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

    Not yet reported Visirna Therapeutics HK Limited 46 participants Est. completion 2027-12-30 1 site
    Other conditions: Homozygous Familial Hypercholesterolemia (HoFH)
    View official trial listing →
  • Active, not recruiting NCT NCT07037771

    A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

    Not yet reported Arrowhead Pharmaceuticals 70 participants Est. completion 2027-08-20 43 sites Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Not yet recruiting NCT NCT07473843

    Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

    Not yet reported Arrowhead Pharmaceuticals 10 participants Est. completion 2028-08 Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Zodasiran, ARO-ANG3

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.